CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $7.9M, lower than 95% of all stocks globally
- PositionOperating margin is -6710.7%, lower than 95% of its Biotechnology peers (median -34.2%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
949.61MEUR1.11B · vs all stocks (USD)
Revenue (TTM)
6.76MEUR7.90M · vs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.9130xvs all stocks
52-Week Change
3.61%vs all stocks
Market Capitalization
949.61MEUR1.11B · vs all stocks (USD)
Enterprise Value
952.53MEUR1.11B · vs all stocks (USD)
Forward P/E
-4.95xvs Biotechnology peers
Enterprise to Revenue
140.89xvs Biotechnology peers
Enterprise to EBITDA
-7.19xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-45.08%vs Biotechnology peers
Revenue (TTM)
6.76MEUR7.90M · vs all stocks (USD)
Revenue per Share (TTM)
0.0360EURUpdated Aug 21, 2026Quarterly Revenue Growth
-89.90%vs Biotechnology peers
Gross Profit (TTM)
6.74MEUR7.87M · vs all stocks (USD)
EBITDA (TTM)
-132.50MEUR-154.79M · vs all stocks (USD)
Net Income (TTM)
-354.14MEUR-413.73M · vs all stocks (USD)
Operating Cash Flow (TTM)
-104.88MEUR-122.53M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-200.71MEUR-234.48M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00EURUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
EPS (Basic)
-1.90EURFY2025 · Dec 31, 2025EPS (Diluted)
-1.90EURFY2025 · Dec 31, 2025Basic Shares Outstanding
186.39MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
186.39MSharesFY2025 · Dec 31, 2025Operating Cash Flow
-114.09MEURFY2025 · Dec 31, 2025Free Cash Flow
-114.34MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
99.31MEURFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-354.14MEURFY2025 · Dec 31, 2025Depreciation & Amortization
3.22MEURFY2025 · Dec 31, 2025Deferred Taxes (CF)
-2.30MEURFY2025 · Dec 31, 2025Stock-based Compensation
26.77MEURFY2025 · Dec 31, 2025Other Non-cash Items
213.14MEURFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
850.00KEURFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.64MEURFY2025 · Dec 31, 2025Capital Expenditures
-247.00KEURFY2025 · Dec 31, 2025Purchase of Investments
-132.94MEURFY2025 · Dec 31, 2025Other Investing Activity
-1.00KEURFY2025 · Dec 31, 2025Net Investing Cash Flow
-133.19MEURFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00EURFY2025 · Dec 31, 2025Long-term Debt Payments
-5.98MEURFY2025 · Dec 31, 2025Common Dividends Paid
0.00EURFY2025 · Dec 31, 2025Other Financing Charges
-17.13MEURFY2025 · Dec 31, 2025Net Financing Cash Flow
183.33MEURFY2025 · Dec 31, 2025Shares Outstanding
193.18MSharesUpdated Aug 21, 2026Float Shares
157.92MSharesUpdated Aug 21, 2026% Held by Insiders
12.67%vs all stocks
% Held by Institutions
49.72%vs all stocks
Total Cash (MRQ)
99.84MEUR116.64M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.4810EURUpdated Aug 21, 2026Total Debt (MRQ)
230.89MEUR269.74M · vs all stocks (USD)
Current Ratio (MRQ)
3.16xvs Biotechnology peers
Book Value per Share (MRQ)
-0.1480EURUpdated Aug 21, 2026Total Assets
249.51MEUR291.50M · vs all stocks (USD)
Total Current Assets
244.47MEURFY2025 · Dec 31, 2025Total Liabilities
278.03MEURFY2025 · Dec 31, 2025Total Non-current Assets
5.04MEURFY2025 · Dec 31, 2025Total Non-current Liabilities
200.66MEURFY2025 · Dec 31, 2025Total Current Liabilities
77.38MEURFY2025 · Dec 31, 2025Cash
16.68MEURFY2025 · Dec 31, 2025Cash Equivalents
82.63MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents
99.31MEURFY2025 · Dec 31, 2025Other Short-term Investments
131.56MEURFY2025 · Dec 31, 2025Accounts Receivable
2.02MEURFY2025 · Dec 31, 2025Inventory
0.00EURFY2025 · Dec 31, 2025Accounts Payable
26.02MEURFY2025 · Dec 31, 2025Short-term Debt
32.31MEURFY2025 · Dec 31, 2025Deferred Revenue
0.00EURFY2025 · Dec 31, 2025Other Current Liabilities
1.00KEURFY2025 · Dec 31, 2025Long-term Debt
27.55MEURFY2025 · Dec 31, 2025Other Non-current Liabilities
52.84MEURFY2025 · Dec 31, 2025Common Stock (Book)
1.93MEURFY2025 · Dec 31, 2025Retained Earnings
-354.14MEURFY2025 · Dec 31, 2025Total Shareholders' Equity
-28.52MEUR-33.32M · vs all stocks (USD)
52-Week Low
2.88EURUpdated Aug 21, 202652-Week High
6.20EURUpdated Aug 21, 202652-Week Change
3.61%vs all stocks
Beta
0.9130xvs all stocks
50-Day MA
3.65EURUpdated Aug 21, 2026200-Day MA
4.31EURUpdated Aug 21, 2026Avg 10-Day Volume
209.49KSharesUpdated Aug 21, 2026Avg 30-Day Volume
306.45KSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-1.90EURUpdated Aug 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -6710.7%, lower than 95% of its Biotechnology peers (median -34.2%)Significant
Operating margin: -67.11Industry median: -0.34Industry P5: -43.55Peers compared: 261
Financial Health
High structural barrier to entryNotable
Barrier to Entry: 39.65
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $7.9M, lower than 95% of all stocks globallySignificant
Revenue (USD): 7,898,605.86Global P5: 30,274,777.221
Levered free cash flow is -$234.48M, lower than 95% of all stocks globallySignificant
Levered free cash flow (USD): -234,483,371.2Global P5: -219,013,500
Companies that share the same coordination system — how they create, deliver, or capture value.
Sichuan Huiyu Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inkon Life Tech Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Oric Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shinva Medical Instrument Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
EyePoint Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
China Resources Boya Bio-Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guangxi Wuzhou Zhongheng Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Frontier Biotechnologies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Star Lake Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Beijing Sun-Novo Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule